ACP
SLNO

Acuta Capital Partners’s Soleno Therapeutics SLNO Stock Holding History

Acuta Capital Partners’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-63,436
Closed -$5.31M – 32
2025
Q2 		$5.31M Sell
63,436
-3,700
-6% -$277K 7.42% 4
2025
Q1 		$4.8M Buy
+67,136
New +$3.27M 5.56% 7

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Acuta Capital Partners's SLNO Position: Q3 2025 in Review

Acuta Capital Partners sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 63,436 shares — an estimated $5.31M sold.

Acuta Capital Partners first reported a position in SLNO in Q1 2025 and held it in 2 quarters. The position peaked at $5.31M in Q2 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Acuta Capital Partners reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Acuta Capital Partners sold 63,436 Soleno Therapeutics shares in Q3 2025, an estimated $5.31M.
  • Acuta Capital Partners first reported a position in Soleno Therapeutics in Q1 2025 and held it in 2 quarters.
  • Acuta Capital Partners's Soleno Therapeutics position peaked at $5.31M in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Acuta Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.